Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2019

Open Access 01-12-2019 | Cough | Research article

Efficacy of glucocorticoids for the treatment of macrolide refractory mycoplasma pneumonia in children: meta-analysis of randomized controlled trials

Authors: Hwan Soo Kim, In Suk Sol, Donghe Li, Miyoung Choi, Yun Jung Choi, Kyung Suk Lee, Ju Hee Seo, Yong Ju Lee, Hyeon-Jong Yang, Hyun Hee Kim

Published in: BMC Pulmonary Medicine | Issue 1/2019

Login to get access

Abstract

Background

Mycoplasma pneumoniae is one of the most common pathogens causing community acquired pneumonia in children. Although the rate of macrolide-refractory Mycoplasma pneumoniae (MRMP) has increased, systemic glucocorticoids as a treatment option has not been validated yet. The purpose of this study was to assess the efficacy of glucocorticoids add-on in the treatment of MRMP in children through systematic review and meta-analysis.

Methods

Data sources

A systematic literature search was conducted using ten electronic bibliographic databases including English, Korean, Chinese and Japanese languages, up to March 8, 2018.

Study selection

The study was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist and selected randomized control trials which compared the efficacy of glucocorticoids add-on to macrolide in the treatment of MRMP in children.

Data extraction

Two independent reviewers extracted: primary outcomes as hospital days, fever duration, and change in C-reactive protein (CRP) and main analysis was performed through meta-analysis with random effects model.

Results

Twenty-four unique randomized controlled trials met the inclusion criteria. The mean length of hospital stay in glucocorticoids treatment group was significantly shorter than that in conventional macrolide-treatment group (Weighted mean difference (WMD) = − 4.03 days). The mean length of fever duration was significantly shorter in the glucocorticoid treatment group in comparison with the conventional treatment group (WMD = -3.32 days). Level of CRP after treatment was significantly lower in the glucocorticoid treatment group than that in the conventional treatment group (WMD = -16.03). Sensitivity analysis and subgroup analysis showed no significant improvement in heterogeneity. As limitations of the study, most of the studies included were from a single country and we were unable to control for heterogeneity across interventions, lack of standardized measures, and different time points of assessments across studies.

Conclusions

Glucocorticoid add-on treatment for MRMP can significantly shorten the duration of fever and hospital stay and decrease the level of CRP. These results should be confirmed by adequately powered studies in the future.

Literature
  1. Lee E, Cho HJ, Hong SJ, Lee J, Sung H, Yu J. Prevalence and clinical manifestations of macrolide resistant mycoplasma pneumoniae pneumonia in Korean children. Korean J Pediatr. 2017;60:151–7.PubMedPubMed CentralView Article
  2. Meyer Sauteur PM, Unger WW, Nadal D, Berger C, Vink C, van Rossum AM. Infection with and carriage of mycoplasma pneumoniae in children. Front Microbiol. 2016;7:329.PubMedPubMed CentralView Article
  3. Yamazaki T, Kenri T. Epidemiology of mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M pneumoniae. Front Microbiol. 2016;7:693.PubMedPubMed CentralView Article
  4. Yang HJ, Song DJ, Shim JY. Mechanism of resistance acquisition and treatment of macrolide-resistant mycoplasma pneumoniae pneumonia in children. Korean J Pediatr. 2017;60:167–74.PubMedPubMed CentralView Article
  5. Youn YS, Lee KY. Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr. 2012;55:42–7.PubMedPubMed CentralView Article
  6. Meijvis SC, Hardeman H, Remmelts HH, Heijligenberg R, Rijkers GT, van Velzen-Blad H, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377:2023–30.PubMedView Article
  7. You SY, Jwa HJ, Yang EA, Kil HR, Lee JH. Effects of methylprednisolone pulse therapy on refractory mycoplasma pneumoniae pneumonia in children. Allergy Asthma Immunol Res. 2014;6:22–6.PubMedView Article
  8. Okubo Y, Michihata N, Morisaki N, Uda K, Miyairi I, Ogawa Y, et al. Recent trends in practice patterns and impact of corticosteroid use on pediatric mycoplasma pneumoniae-related respiratory infections. Respir Investig. 2018;56:158–65.PubMedView Article
  9. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.PubMedPubMed CentralView Article
  10. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.PubMedPubMed CentralView Article
  11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedPubMed CentralView Article
  12. Shao X-L, Liu S-M, Lou W-Y, Zhu G-Z. Methylprednisolone in adjunctive treatment of refractory mycoplasma pneumonia. Chin Gen Pract. 2011;14:186–7.
  13. Xu-yun T, Hong-yu Q. Clinical effect and safety of small-dose methylprednisolone triple therapy on refractory lobar mycoplasma pneumoniae pneumonia in children. Pract J Card Cerebral Pneumal Vasc Dis. 2015;23:74–6.
  14. Ling L. The effect of low-dose methylprednisolone in the treatment of children with refractory mycoplasma pneumoniae pneumonia. J Pediatr Pharm. 2015;21:18–21.
  15. Ming L, Ye-qing H. Small doses of methyl prednisolone sodium succinate and prednisone combined treatment the curative effect of children refractory mycoplasma pneumoniae pneumonia. Medical Innovation of China. 2015;12:10–3.
  16. Jianqin L. Evaluation clinical curative effect of methylprednisolone in treatment of 42 case children with refractory mycoplasma pneumonia. China Contin Med Educ. 2015;7:148–9.
  17. Yan L, Wei L. Effect of low-dose glucocorticoid in the treatment of children with refractory mycoplasma pneumonia. China Mod Med. 2015;22:82–4.
  18. Xuwei F. Methylprednisolone combined with azithromycin in treatment of children with refractory mycoplasma pneumonia (RMPP) efficacy and safety. Prog Biomed Eng. 2015;36:246–8.
  19. Lijun Y. Clinical curative effect analysis of methyl prednisolone auxiliary treatment of refractory mycoplasma pneumonia. China Contin Med Educ. 2015;7:142–3.
  20. Ming-xing R, Guochang X, Linna S, Huan X, Yuejuan S, Li C. Efficacy and safety of methylprednisolone combined with azithromycin on refractory mycoplasma pneumonia in children. Chin Gen Pract. 2015;18:588–91.
  21. Zhang X. Clinical study of glucocorticoid in the treatment of refractory mycoplasma pneumoniae pneumonia. J Clin Pulm Med. 2015;20:1472–5.
  22. Qing L, Hu L, Ling Z, Yajun H. Effect of therapy with glucocorticoids in children with refractory mycoplasma pneumoniae pneumonia. J Pediatr Pharm. 2016;22:25–7.
  23. Jianjun W. Study on the effect of azithromycin and methylprednisolone in the treatment of children with refractory mycoplasma pneumonia. Chin Community Dr. 2016;32:31–3.
  24. Hao W, Jingrong Y, Jinglin O. Clinical effect of methylprednisolone combined with azithromycin in the treatment of children with RMPP. Med Sci J Cent South China. 2016;44:442–6.
  25. Xuan Z, Juanjuan Z, Huichao J, Yang Z. Observation on efficacy of methylprednisolone in treatment of children with refractory mycoplasma pneumoniae. Eval Anal Drug-Use Hosp China. 2016;16:1351–3.
  26. Xiaoqiang F, Chunyan G, Xiaohong H, Shiping L. Clinical analysis of the effects of methylprednisolone on the treatment of refractory mycoplasma pneumoniae pneumonia in children. Transl Med J. 2016;5:92–5.
  27. Hai-yan Q. To observe the curative effect of small dose of glucocorticoid combined with Pulmicort inhalation in the treatment of refractory mycoplasma pneumonia. Contemp Med. 2017;23:37–9.
  28. Chaoyu J, Rongfang M. Hormone refractory mycoplasma pneumonia lavage cytokines. Shaanxi Med J. 2017;46:22–4.
  29. Xiaoyun L, Jinping F, Qiaoziang X. Intravenous methylprednisolone combined with azithromycin in treatment of children with refractory mycoplasma pneumonia and influence on relevant laboratory parameters. J Pediatr Pharm. 2017;23:14–6.
  30. Chun-yan L, Ling-zhi C. Clinical effect of methylprednisolone pluse therapy in treatment of refractory mycoplasma pneumoniae in children. Syst Med. 2017;2:70–87.
  31. Jia-li X, Ying W, Peng C. Clinical effect of methylprednisolone combined with azithromycin sequential therapy in treating children with mycoplasma pneumonia and the impact on serum levels CRP and sTREM-1. Pract J Card Cereb Pneumal Vasc Dis. 2017;25:155–7.
  32. Yu J, Wang X, Wu C. Clinical analysis of methylprednisolone in the treatment of children refractory mycoplasma pneumoniae pneumonia. China Pract Med. 2017;12:7–9.View Article
  33. Wu X. Analysis of the effect of combined use of methylprednisolone and azithromycin on refractory mycoplasma pneumonia in children. Contemp Med Symp. 2017;15:133–4.
  34. Shuqing Z, Yanrong Z. Effect of small doses of methylprednisolone treatment of children with refractory mycoplasma. Med Recapitulate. 2017;23:798–801.
  35. Shan LS, Liu X, Kang XY, Wang F, Han XH, Shang YX. Effects of methylprednisolone or immunoglobulin when added to standard treatment with intravenous azithromycin for refractory mycoplasma pneumoniae pneumonia in children. World J Pediatr. 2017;13:321–7.PubMedView Article
  36. Defilippi A, Silvestri M, Tacchella A, Giacchino R, Melioli G, Di Marco E, et al. Epidemiology and clinical features of mycoplasma pneumoniae infection in children. Respir Med. 2008;102:1762–8.PubMedView Article
  37. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72.PubMedView Article
  38. Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015;385:1511–8.PubMedView Article
  39. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev. 2004;17:697–728.PubMedPubMed CentralView Article
  40. Tanaka H, Narita M, Teramoto S, Saikai T, Oashi K, Igarashi T, et al. Role of interleukin-18 and T-helper type 1 cytokines in the development of mycoplasma pneumoniae pneumonia in adults. Chest. 2002;121:1493–7.PubMedView Article
  41. Shimizu T, Kida Y, Kuwano K. Cytoadherence-dependent induction of inflammatory responses by mycoplasma pneumoniae. Immunology. 2011;133:51–61.PubMedPubMed CentralView Article
  42. Wang JY, Lee CH, Cheng SL, Chang HT, Hsu YL, Wang HC, et al. Comparison of the clinical manifestations of severe acute respiratory syndrome and mycoplasma pneumoniae pneumonia. J Formos Med Assoc. 2004;103:894–9.PubMed
  43. Principi N, Esposito S. Macrolide-resistant mycoplasma pneumoniae: its role in respiratory infection. J Antimicrob Chemother. 2013;68:506–11.PubMedView Article
  44. Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T. Methylprednisolone pulse therapy for refractory mycoplasma pneumoniae pneumonia in children. J Inf Secur. 2008;57:223–8.
  45. Tagliabue C, Salvatore CM, Techasaensiri C, Mejias A, Torres JP, Katz K, et al. The impact of steroids given with macrolide therapy on experimental mycoplasma pneumoniae respiratory infection. J Infect Dis. 2008;198:1180–8.PubMedView Article
  46. Luo Z, Luo J, Liu E, Xu X, Liu Y, Zeng F, et al. Effects of prednisolone on refractory mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol. 2014;49:377–80.PubMedView Article
Metadata
Title
Efficacy of glucocorticoids for the treatment of macrolide refractory mycoplasma pneumonia in children: meta-analysis of randomized controlled trials
Authors
Hwan Soo Kim
In Suk Sol
Donghe Li
Miyoung Choi
Yun Jung Choi
Kyung Suk Lee
Ju Hee Seo
Yong Ju Lee
Hyeon-Jong Yang
Hyun Hee Kim
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2019
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-019-0990-8

Other articles of this Issue 1/2019

BMC Pulmonary Medicine 1/2019 Go to the issue